Quince Therapeutics (NASDAQ:QNCX) Given "Buy" Rating at D. Boral Capital

Key Points

• D. Boral Capital has reiterated a "buy" rating for Quince Therapeutics, setting a price target of $4.00, indicating a potential upside of 138.10% from the current stock price.
• Multiple research firms recently provided varied ratings, with QNCX receiving a consensus rating of "Buy" and an average price target of $8.14.
• Quince Therapeutics reported a quarterly loss of ($0.34) earnings per share, which fell short of analysts' expectations of ($0.28).

D. Boral Capital reiterated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX - Free Report) in a research note issued to investors on Friday,Benzinga reports. D. Boral Capital currently has a $4.00 target price on the stock.

QNCX has been the topic of several other reports. Citigroup initiated coverage on Quince Therapeutics in a research report on Tuesday, August 5th. They issued an "outperform" rating on the stock. Wall Street Zen lowered shares of Quince Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. JMP Securities lowered their price target on shares of Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating for the company in a report on Tuesday, August 12th. Finally, Citizens Jmp began coverage on shares of Quince Therapeutics in a research note on Tuesday, August 5th. They set a "strong-buy" rating and a $9.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. According to MarketBeat, Quince Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $8.14.

Quince Therapeutics Price Performance

Shares of QNCX stock traded up $0.0190 during trading hours on Friday, hitting $1.6290. The company's stock had a trading volume of 37,908 shares, compared to its average volume of 236,128. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 1.45. The business has a fifty day moving average of $1.63 and a 200-day moving average of $1.37. Quince Therapeutics has a twelve month low of $0.5609 and a twelve month high of $2.45. The stock has a market cap of $87.49 million, a price-to-earnings ratio of -1.49 and a beta of 1.02.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). As a group, equities research analysts anticipate that Quince Therapeutics will post -1.21 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nantahala Capital Management LLC purchased a new position in shares of Quince Therapeutics in the 2nd quarter valued at $4,172,000. Ieq Capital LLC purchased a new stake in Quince Therapeutics during the 1st quarter worth $1,073,000. Rockefeller Capital Management L.P. acquired a new stake in Quince Therapeutics in the 2nd quarter valued at $280,000. Shay Capital LLC raised its position in Quince Therapeutics by 60.8% in the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company's stock valued at $518,000 after purchasing an additional 104,616 shares during the period. Finally, Intellectus Partners LLC purchased a new position in Quince Therapeutics in the first quarter valued at about $71,000. 30.75% of the stock is owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.